Skip to NavigationSkip to content


Hyloris and Purna Female Healthcare partner to develop novel women's health product

Image credit: Doc. RNDr. Josef Reischig, CSc.

Hyloris Pharmaceuticals and Purna Female Healthcare (PFH), a spin-off founded by Purna Pharmaceuticals and Creafund, have entered into a partnership to develop and commercialise an innovative combination therapy for the treatment of severe and recurrent vulvovaginal candidiasis (rVVC).

PFH is a special purpose vehicle founded to exclusively develop a local topical combination formulation of the well-known antifungal Miconazole with Domiphen Bromide (MCZ-DB).

Realising the potential of greater collaboration for women living with cancer

Published on 27/01/20 at 11:44am

Following the launch of a new global report, 'Supporting women with cancer', Lynn Talyroe, Senior Vice President, Head of Healthcare Global Government and Public Affairs, Head of Corporate & Government Relations USA at Merck KGaA, discusses the unique challenges faced by women living with cancer and the importance of providing more tailored support.

Despite the number of policies aimed at eliminating and reducing risk factors, and promoting early detection, the number of cancer cases continues to rise globally.

Women scientists receive $41,000 less in funding than men, study shows

Women scientists receive $41,000 less in federal funding than men, according to a study of nearly 54,000 grants to first time principal investigators.

First-time principal investigators who are women received considerably less than their male counterparts from the National Institutes of Health (NIH), the study from Northwestern Medicine and the Kellogg School of Management, says.

Enough talk: Action is required to achieve parity in biotech

Published on 06/08/18 at 11:48am

Liz Lewis, Chief Counsel & Head of Patient Advocacy at Takeda Oncology tackles the crucial and topical issue of diversity within life sciences and beyond, and why the benefits of pushing for greater representation reach far beyond stamping out harassment.

At this year’s JP Morgan Healthcare Conference, the largest gathering of the biopharmaceutical industry, one of the most talked about articles came from two industry journalists pointing out men named Michael outnumbered female CEOs presenting at the conference.

Synergy Vision shortlisted for Women of the Future awards

Published date: 
Medical Communications agency, Synergy Vision, is very excited to have been shortlisted for Women of the Future awards.

Synergy Vision has been shortlisted for the Women of the Future (“WOF”) Awards, the movement recognising and nurturing young female talent in the UK, announced on Monday. The Awards, now in its 10th year and supported by headline sponsor Aviva, are open to women aged 35 or under and celebrate rising talent across business, culture, media and more.

Mylan buys into women’s health

Mylan image

Mylan is to acquire a number of women’s healthcare companies from Indian-based Famy Care that will build upon its 2008 partnership to create a franchise in developing countries.

The $750 million transaction is expected to close in the second half of 2015 and comes less than a year after US-based Mylan purchased Abbott's branded generics business, which also includes a women's healthcare portfolio.

Women in the pharma industry

Published on 03/09/13 at 09:14am
Janssen image

In the past pharma has been accused of being too male-orientated in both the laboratory and the boardroom. The idea of the ‘old boys club’ still haunts the industry, but is this culture changing in the 21st century?

Pharmafocus talks to Jane Griffiths about these issues, a woman who gained a PhD in biochemistry from the University of Aberystwyth in 1982 and rose up the ranks of Johnson & Johnson to become the first female company group chairman of its pharma unit Janssen in the EMEA region.

Ben Adams: How did you get into your current position?

Watson buys women’s health specialists

Watson image

Watson has completed the acquisition of Uteron Pharma, a Belgium R&D-based firm specialising in women’s health products.

The world's third-largest generics pharma company, Watson has bought Uteron to expand into R&D-based pharma products.

The firm is responding to squeezed margins in the global generics market, and paid €4.25 billion ($7 billion) in April last year to acquire rival generics firm Actavis.

The newly-enlarged group will change its name to Actavis, but is looking to diversify away from being a purely generics company.

Addressing the boardroom gender gap

Published on 16/10/12 at 02:30pm

The issue of gender balance within UK boards has moved quickly up the business agenda following last year’s Davies Report. Lord Davies’ Women on Boards report outlined the benefits that a mixed board brings in terms of skills and different perspectives, and recommended that a minimum of 25% of FTSE 100 board members should be female by 2015.

Across Europe the topic is also rising in importance, with a growing feeling that quotas may soon be imposed.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches